Concentrated stock can expose an investor to significant company-specific and market risk. Selling appreciated shares generally realizes gain equal to proceeds minus adjusted basis, not the full position value. Federal long-term capital-gain rates generally range from 0% to 20%; the 3.8% NIIT may also apply, depending on income. Short-term gains and state taxes can change the result.
A position is typically considered critically concentrated when a single holding exceeds 20% of investable assets. At that threshold, a 50% decline in the stock — not an unusual outcome for individual equities over a 5-year period — would destroy 10% of total wealth. The risk management imperative increases nonlinearly as concentration grows beyond that threshold.
Strategy 1: Staged Outright Sale with Tax Management
A staged sale may help manage realized gains and liquidity, but postponing a sale retains market and concentration risk. Capital losses, basis, other income, and future tax rates affect the outcome. Selling across multiple years does not necessarily reduce total taxes or produce a better after-tax result.
Strategy 2: Rule 10b5-1 Trading Plans
Corporate insiders must comply with securities laws and company trading policies. A Rule 10b5-1 plan may provide an affirmative defense only if all applicable conditions are met, including adoption without material nonpublic information and good-faith operation. Directors and officers generally have a cooling-off period ending at the later of 90 days after adoption or two business days after disclosure of the relevant quarterly financial results, capped at 120 days; other covered persons generally have a 30-day period. Overlapping-plan and single-trade restrictions have exceptions. Securities counsel should review adoption, modifications, disclosures, and execution.
Strategy 3: Exchange Funds
An exchange fund may permit an eligible investor to contribute appreciated stock to a partnership and obtain diversified exposure. Nonrecognition under IRC §721 is subject to exceptions, including the investment-company rules. Seven-year distribution rules and fund-specific redemption restrictions require tax review; a seven-year term does not guarantee tax-free diversification. Basis generally carries over, so gains may be deferred, not eliminated. Eligibility, minimums, fees, diversification, and liquidity vary by fund; these investments carry market and partnership risks.
Potential gain deferral, subject to statutory exceptions · Fund-specific eligibility, fees, and redemption restrictions · Seven-year distribution rules may apply · Carryover basis and future tax liability · Illiquidity and investment risk
Strategy 4: Protective Puts and Zero-Cost Collars
A protective put can limit downside below its strike while effective, subject to option terms, premiums, expiration, execution, and counterparty considerations. An 80%-of-price strike does not cap total loss at 20% after costs. Hedging can alter tax treatment and holding periods.
A zero-cost collar pairs a purchased put with a sold covered call whose premiums may offset at inception, excluding fees and other costs. It limits upside as well as downside and may create assignment and tax risks. A tight hedge may trigger constructive-sale treatment under IRC §1259. There is no statutory 20–25% strike-spread safe harbor; transaction terms require individualized tax and legal analysis.
Strategy 5: Charitable Structures
A qualifying Charitable Remainder Trust (CRT) generally does not pay current income tax on investment gains. Distributions to noncharitable beneficiaries may nevertheless include taxable capital gains under statutory distribution tiers; gains are not automatically erased. A CRT may pay an annuity or unitrust amount and must ultimately benefit charity. Any partial charitable deduction depends on valuation, trust terms, eligibility, and deduction limits. Funding is irrevocable, and investment, administrative, and tax risks require professional review.
A Donor-Advised Fund (DAF) involves an irrevocable gift to a sponsoring charity; the donor retains advisory privileges, not ownership or a right to recover the assets. A deduction for eligible appreciated shares may be based on fair market value, subject to holding-period, valuation, percentage-of-income, and other limits. Review assignment-of-income issues before a planned sale. No personal income stream is provided.
A plan may combine staged sales, charitable gifts, or other eligible strategies, but no allocation is appropriate for everyone. Compare costs, liquidity constraints, tax uncertainty, concentration risk, and irrevocable charitable commitments with simpler alternatives. Diversification does not guarantee a profit or protect against every loss.
Conclusion
A concentrated stock position is not a problem to be solved in a single transaction. It is a multi-year wealth management challenge that requires coordinating tax strategy, liquidity planning, regulatory compliance, and charitable intent into a coherent plan. At Braintrust Capital®, concentrated equity management is a core discipline — informed by the CPWA® and CIMA® credentials that address exactly this class of complex, high-stakes wealth management problem.
Braintrust Capital® provides tax-aware financial planning and coordination with clients’ independent CPAs and attorneys. Braintrust Capital® is not a law firm and does not provide legal advice. Tax return preparation and transaction-specific tax opinions should be obtained from qualified tax professionals. Strategies discussed may not be suitable for every client; tax savings and investment results are not guaranteed. Registration does not imply regulatory approval or a particular level of skill or training.
Tax content updated November 3, 2026. Federal rules are summarized; state treatment and individual circumstances may differ.
Federal tax references: IRS charitable remainder trusts · IRC §1259: constructive sales · SEC Rule 10b5-1 guidance